Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Cancer- and cancer treatment-related conditions
Stage/Subtype:  diarrhea
Trial Type:  Supportive care
Trial Status:  Closed
Sponsor of Trial:  NCI
Results 1-14 of 14 for your search:
Start Over
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065713, E-E1295, CLB-9770, SWOG-E1295, NCI-P97-0081, NCT00003057
Phase III Double Blind, Placebo Controlled Study of Sucralfate for Treatment-Induced Diarrhea in Patients Receiving Pelvic Radiation Therapy
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-949252, NCI-P97-0083
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065974, NCCTG-969256, NCI-P97-0127, NCT00003170
Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: RTOG-9809, CDR0000066979, RTOG-DEV-1016, NCT00003825
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069304, NCCTG-N00CA, NCI-P02-0221, N00CA, NCT00033605
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Phase: Phase III
Type: Supportive care, Tissue collection/Repository
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCCTG-N08C9, NCI-2011-02602, CDR0000684240, N08C9, NCT01198145
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: J0326, CDR0000441133, P30CA006973, JHOC-J0326, JHOC-03070804, J0326, NCT00258180
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MDA-2008-0005, CDR0000612205, 2008-0005, NCT00748215
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RP 02-24, RPCI-RP-0224, NCT00084721
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Completed
Age: 1 to 30 at diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000373759, P01CA081403, N2003-01, NANT-2003-01, NCT00093353
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
Phase: Phase I
Type: Supportive care, Treatment
Status: Completed
Age: Under 21
Sponsor: NCI, Other
Protocol IDs: CPTCEF, NCT00143533
Study of the Efficacy of Octreotide for the Treatment of Immunotherapy-Induced Diarrhea (Summary Last Modified 01/92)
Phase: No phase specified
Type: Supportive care
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-92-C-0040, NCI-T91-0270N, T91-0270
Study of Octreotide for Irinotecan-Induced Diarrhea in Patients With Metastatic Colorectal Cancer
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NU-00I1, NU-IRB-119-280, NOVARTIS-NU-00I1
Start Over